Ping An Biomedical Co Ltd

Ping An Biomedical Co Ltd(PASW)のニュースとイベント

$5.360

+2.447 (+45.65%)終値時点

PASW のニュース

PASW のイベント

10/23 17:30

Ping An Biomedical Co. Files $300M Mixed Securities Shelf

Ping An Biomedical Co. files $300M mixed securities shelf

10/23 10:00

Ping An Biomedical Co Ltd Trading Halted

Ping An Biomedical Co Ltd trading halted, volatility trading pause

10/22 16:00

Ping An Biomedical Plans Acquisition of Three Patents from Future Biotechnology for $2M to $2.5M

Ping An Biomedical Co. announced its entry into a letter of intent with Future Biotechnology Group for the planned acquisition of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration ranging from $2M to $2.5M. The planned acquisition shall be subject to a final acquisition agreement to be subsequently prepared and executed by the parties. The planned acquisition is intended to support the company's longer-term healthcare and biomedical R&D strategy and to establish a core intellectual property portfolio in oncology and biotechnology. The planned acquisition is intended to establish the company's position in tumor-related technology areas through targeted intellectual property. The company intends to gradually build a healthcare technology asset reserve that can support not only ownership of core intellectual properties, but also potential pathways such as internal development, collaboration, and licensing. The company expects this intellectual property reserve to provide foundational IP support for the subsequent commercialization and rollout of related healthcare businesses. Upon completion of the planned acquisition, the company intends to incorporate the patents into its healthcare technology IP reserve. Management plans to evaluate appropriate pathways for further development, which may include internal research and development, collaboration with partners, and/or licensing, subject to further assessment and applicable approvals. The company does not expect the planned acquisition, by itself, to generate material revenue in the near term; rather, it is intended as a foundational step to support the Company's longer-term healthcare and biomedical initiatives. The company notes that the planned transaction remains subject to due diligence, the negotiation and execution of definitive agreements, and applicable regulatory and contractual requirements. There can be no assurance that definitive agreements will be entered into or that the acquisition will be completed on the terms contemplated, or at all. The company may update this announcement following execution of definitive agreements to reflect the final terms.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める